Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful hard but unsuccessfully to develop an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last few shares. The 1st CytoDyn article of mine, “CytoDyn: What To Do When It’s Too Good To Be True?”, set away the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such an extremely marketing picture in the Uptick Newswire job interview which I came away with a bad impression of the company.

Irony of irony, my bad impression of the company has grown steadily, however, the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the therapy and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the expertise and also associated intellectual property coming from Progenics to CytoDyn, as well as approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) along with the first new drug program approval ($five million), as well as royalty payments of 5 percent of net sales upon commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and numerous therapies, it has this individual treatments and a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

Its opening banner on its site (below) shows an active company with diverse interests albeit focused on leronlimab, several disease sorts, multiple publications and multiple presentations.

Might all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself through the very start of the interest of mine in this particular company. Judging by the multiples of thousands of diverse commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this question.

CytoDyn is a traditional battleground, or maybe some may say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *